Posted by Michael Wonder on 27 Apr 2021
Sol-Gel Technologies provides update on FDA review of Epsolay
27 April 2021 - Sol-Gel Technologies today announced an update regarding the U.S. FDA approval process for Epsolay (benzoyl peroxide) 5% topical cream for the treatment of Inflammatory lesions of rosacea in adults.
In September of 2020, Sol-Gel was informed by the FDA that the PDUFA goal date for Epsolay is 26 April 2021.
